Loading…
Windlas Biotech (WINDLAS)₹974.25−4.34%Pharmaceuticals
In the Jun 2026 quarter (standalone), Windlas Biotech reported sales of ₹249 Cr, up 18.2% from Jun 2025, and net profit of ₹18.02 Cr, up 0.0% year on year. For the year to Mar 2026, sales were ₹906 Cr and net profit ₹66.11 Cr.
Company filings, standalone accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 153 | 162 | 171 | 175 | 187 | 195 | 203 | 210 | 222 | 233 | 238 | 249 |
| Expenses | 134 | 142 | 149 | 154 | 165 | 170 | 177 | 185 | 194 | 210 | 214 | 221 |
| Operating Profit | 18.94 | 19.93 | 21.93 | 20.93 | 22.91 | 24.92 | 25.90 | 26.93 | 28.92 | 23.91 | 24.93 | 26.94 |
| OPM % | 12.0% | 13.0% | 13.0% | 12.0% | 12.0% | 13.0% | 13.0% | 13.0% | 13.0% | 10.0% | 11.0% | 11.0% |
| Other Income | 3.01 | 3.01 | 4.01 | 4.01 | 5.01 | 4.01 | 5.01 | 5.01 | 4.01 | 5.01 | 4.01 | 5.01 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 1.01 | 0.99 | 2.01 |
| Depreciation | 2.99 | 2.99 | 3.99 | 5.99 | 5.99 | 6.99 | 7.98 | 6.99 | 7.98 | 7.98 | 7.98 | 6.98 |
| Profit before tax | 18.04 | 20.03 | 23.04 | 18.04 | 20.03 | 20.05 | 21.05 | 23.05 | 24.06 | 20.03 | 20.05 | 23.06 |
| Tax % | 23.0% | 24.0% | 25.0% | 26.0% | 23.0% | 24.0% | 22.0% | 24.0% | 25.0% | 25.0% | 21.0% | 23.0% |
| Net Profit | 14.03 | 15.03 | 17.02 | 13.02 | 16.03 | 15.01 | 16.03 | 18.02 | 18.03 | 15.01 | 16.03 | 18.02 |
| EPS (Rs) | 6.74 | 7.25 | 8.14 | 6.44 | 7.48 | 7.28 | 7.75 | 8.42 | 8.43 | 7.08 | 7.58 | 8.54 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 275 | 316 | 321 | 288 | 329 | 428 | 467 | 514 | 632 | 760 | 906 | 942 |
| Expenses | 253 | 291 | 285 | 245 | 289 | 374 | 414 | 454 | 554 | 667 | 801 | 839 |
| Operating Profit | 19.95 | 24.94 | 35.89 | 43.84 | 40.87 | 54.82 | 52.84 | 59.81 | 77.76 | 93.63 | 105 | 105 |
| OPM % | 7.0% | 8.0% | 11.0% | 15.0% | 12.0% | 13.0% | 11.0% | 12.0% | 12.0% | 12.0% | 12.0% | 11.1% |
| Other Income | 1.01 | 4.01 | 5.01 | 2.01 | 1.01 | −29.07 | 7.01 | 10.03 | 13.02 | 18.04 | 18.03 | 18.04 |
| Interest | 6.99 | 4.99 | 4.99 | 3.99 | 1.99 | 0.99 | 0.99 | 0.99 | 0.99 | 3.99 | 4.99 | 5.00 |
| Depreciation | 8.98 | 8.98 | 10.98 | 7.98 | 8.98 | 12.97 | 11.97 | 11.97 | 12.96 | 27.93 | 30.92 | 30.92 |
| Profit before tax | 6.01 | 14.03 | 25.05 | 35.08 | 31.09 | 11.02 | 46.08 | 57.08 | 77.12 | 79.18 | 87.23 | 87.20 |
| Tax % | 20.0% | 35.0% | 33.0% | 36.0% | 27.0% | 55.0% | 16.0% | 25.0% | 25.0% | 24.0% | 24.0% | — |
| Exceptional items | 0.00 | 0.00 | 1.01 | 0.00 | 0.00 | −14.01 | 0.00 | 1.01 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | 5.01 | 9.01 | 17.03 | 22.02 | 22.04 | 5.01 | 39.08 | 43.09 | 58.07 | 61.11 | 66.11 | 67.09 |
| EPS (Rs) | 8.12 | 16.39 | 30.19 | 34.99 | 34.98 | 7.79 | 17.67 | 20.01 | 27.92 | 28.88 | 31.42 | 31.63 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 20.0% | 20.0% | 20.0% | 20.0% | 20.0% | — |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.98 | 5.98 | 5.99 | 5.98 | 5.98 | 5.98 | 10.97 | 9.97 | 9.97 | 9.98 | 10.97 |
| Reserves | 132 | 141 | 158 | 188 | 211 | 194 | 385 | 393 | 441 | 496 | 572 |
| Borrowings | 52.99 | 62.01 | 42.99 | 29.99 | 27.02 | 32.03 | 7.01 | 5.01 | 4.01 | 33.05 | 35.01 |
| Other Liabilities | 90.07 | 94.13 | 93.38 | 73.27 | 100 | 64.99 | 88.57 | 121 | 172 | 223 | 291 |
| Total Liabilities | 281 | 305 | 300 | 298 | 345 | 297 | 492 | 530 | 627 | 762 | 909 |
| Fixed Assets | 56.11 | 56.17 | 58.14 | 62.17 | 68.17 | 96.28 | 91.22 | 109 | 179 | 224 | 214 |
| CWIP | 9.01 | 14.99 | 11.01 | 4.99 | 0.00 | 0.00 | 8.01 | 15.01 | 6.01 | 5.01 | 60.03 |
| Investments | 95.37 | 121 | 124 | 122 | 121 | 23.10 | 65.30 | 107 | 174 | 224 | 269 |
| Other Assets | 121 | 111 | 107 | 110 | 154 | 177 | 327 | 298 | 268 | 308 | 366 |
| Inventories | 27.02 | 40.01 | 27.01 | 19.01 | 48.99 | 41.02 | 59.03 | 75.01 | 62.01 | 81.05 | 62.01 |
| Trade receivables | 54.92 | 60.86 | 58.88 | 61.90 | 64.88 | 78.83 | 111 | 117 | 136 | 167 | 227 |
| Cash & equivalents | 29.09 | 2.01 | 6.01 | 13.03 | 18.04 | 31.08 | 114 | 25.07 | 31.07 | 16.05 | 2.01 |
| Total Assets | 281 | 305 | 300 | 298 | 345 | 297 | 492 | 530 | 627 | 762 | 909 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 46.86 | 6.97 | 38.86 | 21.90 | 20.92 | 10.95 | 8.96 | 60.77 | 109 | 67.72 | 105 |
| Cash from investing activity | −62.09 | −39.11 | −11.03 | −7.01 | −9.03 | −20.03 | −154 | −14.02 | −92.23 | −74.22 | −92.28 |
| Cash from financing activity | 38.07 | 5.01 | −25.03 | −8.01 | −6.01 | 1.01 | 130 | −44.10 | −15.03 | 1.01 | −13.02 |
| Net cash flow | 24.06 | −27.06 | 4.01 | 7.02 | 5.01 | −8.01 | −15.03 | 3.01 | 2.01 | −5.01 | 0.00 |
| Capex | 12.96 | 14.97 | 10.97 | 9.97 | 9.97 | 5.99 | 14.97 | 70.82 | 37.92 | 51.91 | 67.81 |
| Free cash flow | 34.99 | −7.99 | 27.95 | 11.99 | 10.98 | 5.99 | −5.99 | −8.99 | 70.88 | 15.99 | 36.94 |
| CFO / OP % | 249.1% | 34.0% | 122.0% | 80.0% | 84.1% | 33.1% | 34.0% | 117.0% | 163.1% | 95.1% | 115.0% |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 75 | 71 | 69 | 80 | 73 | 69 | 88 | 84 | 80 | 81 | 93 |
| Inventory days | 50 | 63 | 45 | 39 | 86 | 56 | 72 | 85 | 58 | 64 | 41 |
| Days payable | 136 | 119 | 123 | 116 | 142 | 52 | 75 | 97 | 120 | 137 | 155 |
| Cash conversion cycle | −13 | 14 | −11 | 0 | 14 | 71 | 83 | 70 | 16 | 7 | −23 |
| Working capital days | −46 | −37 | 2 | −12 | 3 | 40 | 86 | 72 | 32 | 18 | 14 |
| ROCE % | — | 10.0% | 13.0% | 18.0% | 14.0% | 19.0% | 15.0% | 14.0% | 18.0% | 17.0% | 16.0% |
For the Jun 2026 quarter, Windlas Biotech reported sales of ₹249 Cr, up 18.2% year on year and net profit of ₹18.02 Cr, up 0.0% year on year. The operating margin was 11.0%.
Windlas Biotech's sales for the year to Mar 2026 were ₹906 Cr; over the last twelve months they were ₹942 Cr.
Net profit for the year to Mar 2026 was ₹66.11 Cr, and ₹67.09 Cr over the last twelve months. Earnings per share over the same trailing period were ₹31.63.
Windlas Biotech reported borrowings of ₹35.01 Cr at Mar 2026, against cash and equivalents of ₹2.01 Cr.
Cash from operations was ₹105 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹36.94 Cr.